Introduction
Technique
Hemodynamics
Indications
Acute Myocardial Infarction Without Shock
High-Risk Percutaneous Coronary Intervention
Prior to High-Risk Coronary Artery Bypass Graft Surgery
As a Left Ventricular Vent During VA-ECMO Support
Adverse Events
Recent Insights Regarding the Use of IABP in CS
Cardiogenic Shock After Acute Myocardial Infarction
IABP vs Impella
Large-Volume IABP May Be Better
Non-ACS Cardiogenic Shock
Author, publication year [reference] | Study design (volume of balloon) « insertion site » | Inclusion criteria/study population | No. of pts treated with IABP# | Duration of IABP therapy (range) | Effects on hemodynamics, echocardiography and laboratory tests^ | Clinical outcomes |
---|---|---|---|---|---|---|
Norkiene, 2007 [51] | Retrospective, observational (40 cc IABP) « femoral » | Acute decompensated DCM, listed for urgent OHT or LVAD, NYHA 4, MAP < 65, CI < 2, PCWP > 20, refractory to all means of OMT | 11 | Mean 182 ± 82 h (72 to 360) | MAP ↑; LVEF ↑; CVP ↓ | 27% recovery; 27% LVAD; 18% OHT; 27% died (2 after IABP removal and 1 after LVAD) |
Gjesdal, 2009 [52] | Retrospective (40–50 cc IABP) « femoral » | IABP: Terminal HF, IABP as an intended BTT due to clinical deterioration not responding to OMT Control: Pts who received OHT in a hemodynamic stable situation (without IABP) | 40 (control group: 135) | Mean 21 ± 16 days (3 to 66) from onset IABP to OHT Mean 25 ± 21 days (1 to 49) from IABP to MCS | Creatinine ↓; urea ↓; ASAT and ALAT ↓; bilirubin ↓; sodium ↑; potassium ↓ | 95% OHT, but 15% needed escalation to ECMO (10%) and LVAD (5%); 5% died (2.5% on IABP and 2.5% on LVAD); equal post-OHT mortality after 30 d, 1 y, and 3 y between IABP and control; post-OHT RHC and TTE variables equal after 30 d and 1 y |
Russo, 2012 [5] | Retrospective, observational (size NA) « subclavian » | IABP to support severe decompensated HF while awaiting OHT | 17$ | Mean 17 ± 13 days (3 to 48) | NA | 82% OHT; 12% needed escalation to VAD (further outcome unknown); 6% still waiting for OHT; 0% died |
Umakanthan, 2012 [32] | Retrospective, observational (size NA) « axillary& » | End-stage HF and failure on or intolerance to inotropes | 18 | Mean 27 ± 18 days (5 to 63) Median 19 days | CI ↑; mPAP ↓; sPAP ↓; CVP ↓ | 72% OHT; 28% died (6% despite escalation to LVAD); longest walking distance 5.5× ↑; 1 m survival 89%; 6 m survival 72% |
Mizuno, 2014 [53] | Prospective, non-randomized, observational, multicenter cohort (size NA) « femoral » | ADHF who meet the modified Framingham criteria, > 20 y, and considered suitable by the attending physicians; IABP vs control (without IABP) | 123 (control group: 4678) | NA | NA | 71% discharged alive; 29% mortality during hospitalization; mean length of hospital stay 48 days |
Ntalianis, 2015 [54] | Prospective, unicenter, observational (size NA) « femoral » | End-stage HF, NYHA IV, INTERMACS 1 or 2, despite OMT, severe LV and RV systolic dysfunction, with contra-indications for durable HRT, IABP as prolonged support in order to improve the RV function to recover or regain LVAD candidacy | 15 | Mean 73 ± 50 days (13 to 155) Median 72 days | RAP ↓; mPAP ↓; CI ↑; RVSWI ↑; PCWP ↓; creatinine ↓; total bilirubin↓; LVEF ↑; RVEDD ↓; Sm ↑ | 20% recovery (without MCS and all alive/NYHA1 after 6 m); 40% LVAD after a mean of 66 d (reversal of previous contra-indications by IABP); 40% died |
Sintek, 2015 [55] | Single-centre, retrospective (mean size 42 cc) « femoral » | Systolic CHF who developed CS refractory to OMT and, INTERMACS 1 or 2, pts. who received LVAD after bridge with IABP | 54 | Median 2 days for decompensated pts and 3 days for stabilized pts | CI ↑; PCWP ↓; CPI ↑; UP ↑; sPAP ↓ only in subgroup of responders | 57% stabilized*; 43% decompensated (26% medication increase; 11% escalation to MCS); 17% died |
Tanaka, 2016 [4] | Single-centre, retrospective (size 34/40/50 cc) « subclavian& » | Advanced DCHF (clinical diagnosis confirmed by RHC), 56% on inotropes, mean CI 1.9 ± 0.6, as a bridge to definitive HRT | 88 | Median 21 ± 22 days (4 to 135) | CVP↓; mPAP ↓; PCWP ↓; CI ↑; creatinine ↓ | 93% of patients LVAD, OHT, or recovery (3.4% with escalation to MCS); 7% died; 96% able to walk > 3×/d and received physical rehabilitation during IABP; TMST ↑ |
Den Uil, 2017 [56] | Single center, retrospective (50cc IABP) « femoral » | Inotrope-dependent HF with signs of hypoperfusion and tissue hypoxia, INTERMACS 1/2 | 27 | Median 4 days (3 to 9) | MAP ↑; sVO2 ↑; RAP ↓; fb ↓; lactate ↓; sodium ↑ | 67% successful (26% recovery; 19% LVAD; 22% OHT); 7% escalation to ECMO; 26% died; 30-day survival 67%; 1 y survival 63% |
Annamalai, 2017 [10] | Single-centre, prospective (50 cc IABP) « femoral » | Stage D HF, NYHA 3/4, INTERMACS 2/3, inotrope-dependent with persistently low CO, within 48 h of LVAD surgery | 10 | < 48 h | LVSW ↓; LVESP ↓; DPTI ↑; PAP ↓; myocardial oxygen supply/demand ratio ↑; PVR ↓; CPO ↑ | 100% successful LVAD |
Hsu, 2018 [26•] | Single-centre, retrospective, cohort study (size NA) « femoral » | > 18 y, CS (89% systolic CHF) defined as SBP < 90 for > 30 min with evidence of poor end-organ perfusion or need for inotropic support | 74 | NA | CI ↑; SVR ↓; HR ↓; SBP ↓; DBP ↓; RAP ↓; PCWP ↓; PAP ↓; LVCPI ↑; | 20% recovery; 45% LVAD; 7% OHT; 4% urgent escalation to MCS; 24% died |
Morici, 2018 [57] | Bicentre, prospective, phase II study (size NA) « femoral » | ≥ 18 y, < 80 y, severe LV dysfunction, SBP < 90, or MAP < 60 after fluid challenge or with RAP > 12 or PCWP > 14 with ≥ 1 sign of ongoing organ hypoperfusion, failure of OMT (88% after failure of inotropes) | 17$ | Median 7 days (IQR 4 to 9) | NA for IABP alone group | 12% recovery; 53% LVAD; 12% OHT; 6% escalation to ECMO; 18% died |
Fried, 2018 [28•] | Single-centre, retrospective, cohort study (size NA) « femoral except for 1 axillary» | ≥ 18 y, ADCHF with CS (CI < 2.2 and SBP < 90 or need for vasoactive medications to maintain this level) (87% on ≥ 1 inotrope and 28% on ≥ 1 vasopressor) | 132 | Median 96 h (IQR 48 to 144) for entire cohort Median 111 h (IQR 48 to 168) for those who received LVAD or OHT Median 84 h (IQR 44–235) for those with clinical deterioration | CO and CI ↑; mPAP ↓ | 78% discharged after HRT or recovery; 16% recovery; 52% LVAD; 6% OHT; 8% escalation to other MCS; 18% died; 84% overall 30-d survival |
Imamura, 2018 [6•] | Single-centre, retrospective (size NA) « subclavian » | Advanced HF, IABP to treat hemodynamic deterioration (69% on inotropes) | 91 | Mean 25 ± 20 days; 65% continued IABP support for ≥ 14 days | PCWP ↓; CVP ↓; CI ↑; creatinine ↓; lactate ↑ | 12% recovery; 69% LVAD or OHT; 4% escalation to other MCS; 9% died |
Malick, 2019 [50••] | Single-centre, retrospective, cohort study (size NA) « femoral » | ≥ 18 y, ADHF with CS (CI < 2.2 and either SBP < 90 or need for vasoactive medications to achieve this SBP) | 132$ | Median 3 days (IQR 2 to 5) | CO and CI ↑; CPO ↑; CPI ↑; CVP ↓; SVR ↓; mPAP ↓ | 16% recovery; 62% HRT; 22% died; (8% escalation to MCS of which ½ died and ½ received OHT) |
Bhimaraj, 2020 [7•] | Single-centre, retrospective, (size NA) « axillary » | Advanced HF who needed maintenance of hemodynamic support until HRT (71% on inotropes), mean sVO2 54% | 195 | Median 19 days (IQR 12 to 43), max 169 days | WBC ↓; BUN ↓; bilirubin ↓ | 68% successful HRT (62% OHT and 7% LVAD); 9% escalation to MCS; 11% IABP removal due to complications; 8% died and 3% IABP removal because of lack of candidacy for HRT |